Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13275271 | 1.00 | HSD11B1 (0.34) | HSD11B1ESR2 | |
| SCHEMBL3303681 | 1.00 | HSD11B1 (0.34) | HSD11B1ESR2 | |
| SCHEMBL282182 | 0.87 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL3346298 | 0.85 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL3349938 | 0.85 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL2523456 | 0.85 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL3346296 | 0.85 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL13275442 | 0.83 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL13275445 | 0.83 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL13275443 | 0.83 | HSD11B1 (0.32) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545685-B2 | Dispiropyrrolidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-02-10 | — | — | US | disclosed |
| US-20220106324-A1 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-04-07 | — | — | US | disclosed |
| EP-2684880-B1 | DISPIROPYRROLIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2018-02-28 | — | — | EP | disclosed |
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20140121196-A1 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-01 | — | — | US | disclosed |
| EP-2684880-A1 | DISPIROPYRROLIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-20130165424-A9 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-27 | — | — | US | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120264738-A1 | DISPIROPYRROLIDINE DERIVATIVES | SUGIMOTO YUUICHI (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264738-A1 | DISPIROPYRROLIDINE DERIVATIVES | MDM2, TP53, TP53BP1 | HSD11B1 2892/4885ESR2 1398/4885 |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | HSD11B1 1946/4885ESR2 928/4885 |
| US-12545685-B2 | Dispiropyrrolidine derivatives | TP53, MDM2, TP53BP1 | HSD11B1 2315/4885ESR2 556/4885 |
| US-20140121196-A1 | DISPIROPYRROLIDINE DERIVATIVES | MDM2, TP53, TPD52L2 | HSD11B1 2848/4885ESR2 1508/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | HSD11B1 1946/4885ESR2 928/4885 |
| US-20130165424-A9 | DISPIROPYRROLIDINE DERIVATIVES | MDM2, TP53, TP53BP1 | HSD11B1 2892/4885ESR2 1398/4885 |
| US-20220106324-A1 | DISPIROPYRROLIDINE DERIVATIVES | MDM2, TP53, TP53BP1 | HSD11B1 2892/4885ESR2 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.